T here is an acute need for new medications to treat pain. Impor tant sources of therapeutics for pain manage ment and other human conditions are natural products -complex, biologi cally active small molecules made by living organisms. But compounds isolated directly from natural sources often do not have the optimal properties to be drugs. Therefore, a major challenge faced by those using natural products as leads for drug discovery is how to access a diverse range of closely related molecular structures for biological testing. This can be accomplished using chemi cal synthesis, but the complex structures of natural products often make that approach challenging.
The difficulties of accessing structural analogues have hampered efforts to inves tigate a family of natural products called paralytic shellfish toxins (PSTs) as candidate therapeutics for pain 1 . Many PSTs are highly potent (they elicit a strong response from their molecular biological targets) and are therefore highly toxic, which has hindered their devel opment as drugs and has generated interest in accessing less potent analogues. Writing in ACS Chemical Biology, Lukowski et al. 2 report the biosynthetic pathway that gener ates PSTs to which sulfo groups (SO 3 − ) have been added, which are less toxic members of this family of compounds. The sulfotrans ferase enzymes characterized in the study modify extremely complex substrate mol ecules, and therefore might facilitate access to other less toxic analogues of PSTs for drug development.
PSTs are produced by marine micro organisms, including cyanobacteria and dino flagellates 3, 4 . They are responsible for the numbness, tingling and moresevere symp toms of paralytic shellfish poisoning (caused by eating shellfish contaminated with these toxins), and interfere with the voltagegated sodium channels that are responsible for trans mitting signals in the nervous system. Previous efforts to isolate PSTs revealed that microbes often make analogues that bear one or more sulfo groups, leading to the discovery that this chemical modification reduces the potency and toxicity of these natural products 5, 6 . The biosynthetic pathways and enzymes involved in the installation of these sulfo groups were not understood until a few years ago. The first insights were obtained from assays that used poorly characterized enzyme preparations isolated from dinoflagellates 7, 8 . These studies suggested that the sulfo groups were probably added to PSTs at a late stage of the biosynthetic pathway. More recently, the identification of the cyanobacterial genes encoding the bio synthetic machinery that produces saxitoxin, a highly potent PST, have enabled a molecular understanding of PST assembly 9 . Saxitoxin is assembled through transforma tions that convert the amino acid larginine into a series of increasingly elaborate structures. Previous work 10 had identified two putative sulfotransferase enzymes (SxtN and SxtSUL) encoded by saxitoxin's biosynthetic gene clusters, and had found that SxtN can attach a sulfo group to a particular nitrogen atom in saxitoxin to generate an analogue called gonyautoxin 5 ( Fig. 1) . However, the position on saxitoxin at which the second sulfo transferase (SxtSUL) installs a sulfate (SO 4 − ), and the order in which the enzymes are used in nature, were not determined.
Lukowski et al. have now characterized the ability of purified SxtN and SxtSUL to modify saxitoxin and other PSTs. Researchers from the same group had previously shown 11 that an oxygenase enzyme called GxtA catalyses the selective addition of a hydroxyl (OH) group to a normally unreactive carbon cen tre in saxitoxin (Fig. 1 ). In the current work, the authors combined SxtN and SxtSUL with GxtA, and thereby not only confirmed that SxtN installs a sulfo group on the previously identified nitrogen atom, but also discovered that SxtSUL selectively sulfates the hydroxyl group generated by GxtA.
Unlike the nonenzymatic transformations typically used in the chemical synthesis of natural products, these enzymatic re actions are highly selective for single sites on the PST scaffold, and tolerate the presence of the many densely packed, reactive chemical groups that are embedded in the complex molecular architecture of PSTs. Lukowski et al. were therefore able to produce a vari ety of sulfated PSTs directly from saxitoxin. When they measured the biological activity 2 have worked out the biosynthetic pathway that converts saxitoxin into less toxic sulfated analogues in microbes. They find that SxtN, a sulfotransferase enzyme, attaches a sulfo group (SO 3 − ) specifically to a nitrogen atom in saxitoxin, forming the compound gonyautoxin 5. The GxtA enzyme then selectively adds a hydroxyl (OH) group to the other end of the molecule, forming M1β, and a second sulfotransferase, SxtSUL, converts the hydroxyl group into a sulfate group (SO 4 − ), forming the C2 analogue. The work might allow less toxic sulfated PST analogues to be prepared using a combination of conventional chemical synthesis and enzymatic chemistry. PAPS and NADH are enzyme cofactors; VanB is a partner enzyme of GxtA. 
Enzymes that detoxify marine toxins
Potent microbial toxins found in shellfish are possible starting points for drug discovery, but analogues are needed for biological testing. Toxin-modification enzymes now suggest a new approach for producing these analogues.
of these compounds, the results confirmed that the addition of multiple sulfo groups to PSTs reduces the compounds' binding affini ties to voltagegated sodium channels. This strongly suggests that sulfo groups reduce PST toxi city, further highlighting their potential for incorporation into PSTbased drug candidates. The use of biosynthetic enzymes to modify PSTs represents a strategy that is distinct from the chemicalsynthesis approaches more frequently used to make analogues of these natural products 12 . Although many of those synthetic efforts have been successful, they often involve long sequences of reactions and deliver low yields of products as a con sequence of the challenging architectures of the PSTs -which contain an abundance of reactive oxygen and nitrogen atoms that com plicate the use of morestandard chemical reactions. Lukowski and colleagues' find ings now offer researchers the opportunity to combine conventional synthetic chemistry with biocatalysis, using enzymes to further modify PST scaffolds obtained by synthetic routes. This could potentially streamline access to sulfated versions of these natural products. It might eventually even be possible to use this approach to make nonnatural PST analogues for evaluation as candidate therapeutics.
However, substantial barriers must be surmounted before these sulfotransferase enzymes can be fully integrated into PST syn theses. Their catalytic efficiency is very low, and they have not yet been used on a large scale -Lukowski a n d c o l l e a g u e s worked at a sub milligram scale, but multigram quanti ties of PST analogues would eventually be needed for the pre clinical development of drug candi dates. Also, the reactivity of the enzymes towards nonnatural PST scaffolds, or towards members of related toxin families, has yet to be evaluated. If the reactiv ity and selectivity of the sulfotransferases can be optimized using enzyme engineering, these biocatalysts will become powerful synthetic tools in the search for new pain therapeutics. 
K E N G O N O Z A K I & E D WA R D A . M I AO
I nflammation can help to eliminate infection, but excessive inflammation can cause damage to the body. The sensor pro teins that trigger an inflammatory immune response must therefore be carefully regulated. Some intracellular immunesensor proteins detect components in a cell that become abnor mal or altered during a cellular crisis. Signs of cellular crisis are sometimes produced in the absence of an infection, so mechanisms are needed to prevent the proteins from trigger ing an inappropriate inflammatory response. Sharif et al. 1 report a structural study on page 338 that investigates an immunesensor protein called NLRP3, revealing that a protein called NEK7 acts as a 'licence' that enables this protein to cause inflammation.
When an immune sensor recognizes a hallmark of infection in the cytoplasm, this can activate the protein and lead to the assembly of a multiprotein complex called an inflamma some. The activation of proteins that function downstream of an inflammasome can potently drive both inflammation and cell death 2 . Different types of inflammasome can form depending on the sensor components involved. Certain inflammasomes respond to a highly specific trigger: for example, those in mammalian cells containing the sensor pro tein NLRC4 respond to the presence of the bacterial protein flagellin 3, 4 .
Proteins that are normally present in mammalian cells do not seem able to trigger the accidental formation of NLRC4containing inflammasomes, given the lack of reports of such aberrant events. By contrast, inflamma somes that contain NLRP3 are activated when NLRP3 recognizes -by an as yet unknown mecha nism -hallmarks of cellular catastrophe, such as extremely low concentrations of potassium in the cytoplasm, or signs of dysfunction in organelles called mitochondria 2 . Such events can arise from tissue damage that is un related to infection, and NLRP3 activation in such cases has been implicated as a possible cause of inflammatory diseases such as atherosclerosis.
It is widely accepted that the tightly regulated formation of NLRP3containing inflammasomes occurs in two steps. In the first step, NLRP3 is primed for action by other immunesensor proteins called TLRs, which can detect components of microorganisms. This priming step occurs in two ways 2 : NLRP3 can undergo a modification, such as the addi tion of a phosphate group or the removal of an attached ubiquitin protein. Further priming is achieved by a rise in expression of the gene that encodes NLRP3, increasing the chance that NLRP3 will detect any abnormalities. The second step, activation, then results in NLRP3 proteins binding together to form part of a discshaped inflammasome complex that is probably similar to those of other inflamma somes containing proteins of the NLR family (which includes NLRP3 and NLRC4) 5, 6 . This activation step occurs during a cellular cata strophe, but the biochemical and structural mechanisms involved are unknown.
Researchers have long sought to determine the structure of NLRP3 as it forms an inflam masome, in the hope of gaining insights into how this protein functions. However, such efforts have been unsuccessful, perhaps because unknown protein partners that interact with NLRP3 were missing from earlier attempts.
The discovery [7] [8] [9] that the enzyme NEK7 is essential for NLRP3 signalling provided a missing part of the puzzle. NEK7 regulates pro cesses that occur during cell division, such as the breakdown of the nuclearenvelope structure 10 , so it was surprising to find that it has a separate role in inflammation. This suggested that NLRP3containing inflammasome formation doesn't occur during cell division because NEK7
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A licence to kill during inflammation
Inflammasomes are protein complexes that fight infection by driving inflammation or cell death. It now seems that the protein NEK7 provides a 'licence' for the formation of inflammasomes containing the protein NLRP3. See Article p.338 "These findings offer researchers the opportunity to combine conventional synthetic chemistry with biocatalysis."
